Skip to content

Prospective primary human lung cancer tumoroids to predict treatment response

Prospective primary human lung cancer tumoroids to predict treatment response - Lung cancer tumoroids

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON54034
Enrollment
600
Registered
2021-09-02
Start date
2022-11-14
Completion date
Unknown
Last updated
2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer tumour material

Interventions

There is no intervention or research product. An extra tube of blood will be withdrawn from an existing line during a regular diagnostic procedure.

Sponsors

Maastro
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • All patients selected to undergo primary surgical resection of a primary lung cancer. All types of resection are eligible, e.g. wedge resection, segmental resection, lobectomy, pneumonectomy. • All patients with (suspected) lung cancer that will undergo a bronchoscopy or endobronchial ultrasound guided transbronchial needle aspiration (EBUS/EUS-TBNA) bronchoscopy.

Exclusion criteria

Exclusion criteria: - Incompetent -

Design outcomes

Primary

MeasureTime frame
To establish matched normal and primary human lung cancer tumoroids from patient-derived (tumor) tissue material

Secondary

MeasureTime frame
1. To define oncogenic drivers in lung cancer tumoroids 2. To investigate the stability of (epi-) genetic and phenotypic tumor heterogeneity of cultured tumoroids compared to a primary/secondary biopsy. 3. To predict sensitivity and to get insight in the molecular biology of the response to immunotherapy, radiotherapy, cytotoxic and targeted agents. 4. To compare treatment response in normal lung organoids and lung cancer tumoroids 5. To develop biomarker(s) of tumor response to be able to select patients who will benefit from novel treatment strategies. 6. To analyze (ct)DNA, RNA, proteins, metabolites, and microvesicles secreted by lung cancer cells in tumoroids-derived culture supernatants and corresponding patient-derived blood samples.

Countries

Netherlands

Contacts

Public ContactC. Overhof-Wedick

Maastro

chantal.overhof@maastro.nl088-4455600

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)